NASDAQ:MIST - Milestone Pharmaceuticals Stock Price, Forecast & News

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its earnings results on Wednesday, November, 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.04. View Milestone Pharmaceuticals' Earnings History.

Milestone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Milestone Pharmaceuticals.

6 Wall Street analysts have issued twelve-month price targets for Milestone Pharmaceuticals' shares. Their forecasts range from $26.50 to $32.00. On average, they anticipate Milestone Pharmaceuticals' stock price to reach $29.50 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Milestone Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Milestone Pharmaceuticals.

News coverage about MIST stock has been trending extremely negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Milestone Pharmaceuticals earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Milestone Pharmaceuticals.

Milestone Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 15,200 shares, an increase of 19.7% from the December 31st total of 12,700 shares. Based on an average daily volume of 18,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.1% of the shares of the company are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Some companies that are related to Milestone Pharmaceuticals include Cambrex (CBM), Xencor (XNCR), PPD (SDGR), Esperion Therapeutics (ESPR), Eidos Therapeutics (EIDX), Forty Seven (FTSV), Heron Therapeutics (HRTX), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Tricida (TCDA), Ligand Pharmaceuticals (LGND), Aimmune Therapeutics (AIMT), Arvinas (ARVN), Akcea Therapeutics (AKCA) and Alder Biopharmaceuticals (ALDR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Walt Disney (DIS), Gilead Sciences (GILD), Enterprise Products Partners (EPD), AT&T (T), Verizon Communications (VZ), Amarin (AMRN), CareDx (CDNA), eHealth (EHTH), LYFT (LYFT) and Novavax (NVAX).

(MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Milestone Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Oxford Asset Management LLP (0.08%). Company insiders that own Milestone Pharmaceuticals stock include Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP. View Institutional Ownership Trends for Milestone Pharmaceuticals.

MIST stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP. View Insider Buying and Selling for Milestone Pharmaceuticals.

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MIST stock can currently be purchased for approximately $20.73.

Milestone Pharmaceuticals has a market capitalization of $507.79 million. Milestone Pharmaceuticals employs 20 workers across the globe.View Additional Information About Milestone Pharmaceuticals.

The official website for Milestone Pharmaceuticals is http://www.milestonepharma.com/.

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]